Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.50 USD
Change Today +0.14 / 1.50%
Volume 12.0K
ADMA On Other Exchanges
As of 2:46 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

adma biologics inc (ADMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $14.00
52 Week Low
05/8/15 - $7.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADMA BIOLOGICS INC (ADMA)

Related News

No related news articles were found.

adma biologics inc (ADMA) Related Businessweek News

No Related Businessweek News Found

adma biologics inc (ADMA) Details

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. Its lead product candidate is RI-002, which is in Phase III clinical trial intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

60 Employees
Last Reported Date: 03/9/15
Founded in 2004

adma biologics inc (ADMA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $572.6K
Chief Financial Officer and Vice President
Total Annual Compensation: $398.1K
Chief Scientific & Medical Officer and Execut...
Total Annual Compensation: $377.0K
Compensation as of Fiscal Year 2014.

adma biologics inc (ADMA) Key Developments

Biotest AG Continues Cooperation with ADMA Biologics, Inc. for RSV Hyperimmunoglobulin RI-002 (English)

Biotest AG continued cooperation with ADMA Biologics, Inc. for the RSV hyperimmunoglobulin RI-002 - Biologic Licence Application submitted to Food and Drug Administration after successful phase III trial Dreieich, September 30, 2015. In accordance with the license agreement entered on December 31, 2012 Biotest AG (Biotest) made a milestone payment following ADMA Biologics, Inc., New Jersey, USA, (ADMA) submission of the Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for their most advanced product RI-002. Biotest has acquired the license of the ADMA product for Europe and other markets. In addition to the marketing and sales license subsidiary Biotest Pharmaceuticals Corp., Boca Raton, USA, provides ADMA with manufacturing services and plasma supply. ADMA is pursuing an indication for the use of this specialty intravenous immunoglobulin product for the treatment of patients diagnosed with Primary Immune Deficiency Disease (PIDD) and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.

FDA Accepts ADMA Biologics License Application for RI-002

ADMA Biologics, Inc. announced that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application for RI-002 intended for the primary immunodeficiency (PI) population. PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly, affecting approximately 250,000 people in the United States. The PDUFA date for the FDA to complete the review is scheduled for the second half of 2016. RI-002 demonstrated positive results in a Phase III study in patients with PI, meeting its primary endpoint, of no serious bacterial infections (SBI) reported. These results, included in the submission, more than meet the requirement specified by the FDA guidance of a% 1 SBI per patient-year, which were presented at the 2015 American Academy of Allergy Asthma and Immunology Annual Meeting.

ADMA Biologics, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 03:30 PM

ADMA Biologics, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 03:30 PM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Adam S. Grossmann, Founder, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMA:US $9.50 USD +0.14

ADMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.7x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMA BIOLOGICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at